-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cediranib (Cediranib) is an oral anti- angiogenic VEGF receptor 1-3 inhibitor .
Cediranib (Cediranib) is an oral anti- angiogenic VEGF receptor 1-3 inhibitor Cediranib (Cediranib) is an oral anti- angiogenic VEGF receptor 1-3 inhibitor Vascular ovarian cancer
ICON6 (NCT00532194) is an international three-arm, double-blind, placebo-controlled randomized trial.
Total prognosis
Total prognosisAfter a median follow-up of 25.
After a median follow-up of 25.
Time from randomization to follow-up treatment
Time from randomization to follow-up treatmentThere is strong evidence that the Grambsch-Therneau test deviates from the non-proportional hypothesis (P=0.
Although there is a statistically significant difference in progression-free survival, a 14% relative reduction in the risk of death is traditionally not statistically significant.
In this study, the improvement of PFS and the increase in average survival time indicate that cediranib may have certain activity in the treatment of recurrent ovarian cancer and should be further studied.
Original source:
Ledermann JA, Embleton-Thirsk AC, Perren TJ et al.
org/10.
1016/j.
esmoop.
2020.
100043">Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised tria in this message
